• News
  • SAN DIEGO
  • BioTech

JPMorgan recommends Acadia

The JPMorgan investment bank initiated coverage of Acadia Pharmaceuticals (Nasdaq: ACAD) on Thursday with a target price of $33, far above its current price in the $19 range.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Acadia Pharmaceuticals Inc.

Company Website

3911 Sorrento Valley Blvd.
San Diego, CA 92121

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ACAD
32.98
  0.14  
+ 0.43%
2,097,564,000
33.49
15.64

Insider Trade Data

Date Insider Shares Type Value
12/15/2014 Gray, Mary Ann 12,250 Sell $388,815
12/15/2014 Hacksell, Uli 30,000 Exchange $60,000
12/15/2014 Hacksell, Uli 30,000 Sell $929,916
12/15/2014 Gray, Mary Ann 12,250 Exchange $115,780
12/09/2014 Baity, Glenn F 8,000 Exchange $12,400

Acadia Pharmaceuticals Inc. Executive(s):

Uli Hacksell

  • Chief Executive Officer, President

Similar Companies

NAICS - 325412 - Pharmaceutical Preparation Manufacturing
SIC - 2834 - PHARMACEUTICAL PREPARATIONS
SIC - 2835 - IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES
NAICS - 541711 - Research and Development in Biotechnology
SIC - 8731 - COMMERCIAL PHYSICAL AND BIOLOGICAL RESEARCH
SIC - 8733 - NONCOMMERCIAL RESEARCH ORGANIZATIONS
Subscribe Today!